🇺🇸 FDA
Pipeline program

Armodafinil 100 to 250 mg/day

C10953/3024/ES/MN

Phase 3 small_molecule completed

Quick answer

Armodafinil 100 to 250 mg/day for Excessive Daytime Sleepiness is a Phase 3 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Excessive Daytime Sleepiness
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials